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Abstract
The protein binding rate of a nonsteroidal antiinflammatory drug (NSAID), flurbiprofen (FP), is about
99%, indicating its low tissue transfer. 6-Methoxy-2-naphthyl acetic acid (6MNA) is an active metabolite
of an NSAID, nabumetone (Relifen®). These drugs strongly bind to human serum albumin (HSA) site
II, suggesting that protein binding inhibition by 6MNA may promote tissue transfer of FP. We
investigated cell membrane permeability of FP in the presence of 6MNA using swine kidney cell line
LLC-PK1, in which the upper and lower sides of the cell membrane plate (Transwell®) were regard d
as the tissue and vascular sides, respectively. After adding 6MNA to HSA solution containing FP on
the lower side, the FP levels in the upper and lower solutions and cells were measured. FP transfer to
the upper side was significantly promoted by the addition of 6MNA with regard to the total and free
FP levels. No change in the FP level was noted in cells or wells. It was suggested that concomitant
nabumetone may promote transfer of site II binding drugs, such as FP, to the target tissue, increasing
the effect even at a low dose. 
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INTRODUCTION
The serum protein binding rate of a nonsteroidal
antiinflammatory drug (NSAID), flurbiprofen (FP), is
very high (about 99%), indicating its low tissue transfer1).
6-Methoxy-2-naphtyl acetic acid (6MNA) is an active
metabolite of an NSAID, nabumetone (Relifen®). Its
biological half-life is long, and the therapeutic
concentration is high. These drugs strongly bind to site
II of human serum albumin (HSA)2). Thus, we considered
that protein binding inhibition by 6MNA may promote
tissue transfer of FP and increase its effect at a low
dose. We previously measured the drug binding ability
to binding sites on HSA and α1-acidic glycoprotein
(AGP) molecules and laboratory test values affecting the
binding, and established a simple diagnostic method of
pharmacological distribution to determine the timing of
drug administration and increase the pharmacological
effect3-6). We also reported that protein binding inhibition
by a free fatty acid (FFA), oleic acid (Ole), elevated the
blood FP level2). However, we have not investigated cell
membrane permeability involved in tissue transfer of
the drug, a only r ported the protein binding-
inhibitory phenomenon and pharmacokinetic changes in
the body. We pr viously performed a basic study on cell
membrane permeability of probe drugs in the presence
of protein binding inhibitors using cells cultured on
plates for cell permeation, and established this method7).
Thus, using swine kidney cell line LLC-PK1, we
investigated cell membrane permeability of FP in the
presence of 6MNA.
MATERIALS AND METHODS
1. Preparation of LLC-PK1 cell membrane plates7 )
Commercial swine kidney-derived LLC-PK1 cells
were seeded in a culture flask (25 cm2) containing ell
growth medium (Earle’s Medium 199, GIBCO)
supplemented with antibiotics (penicillin-streptomycin,
GIBCO) and fetal bovine serum (FBS, GIBCO). The
cells were cultured in a CO2 incubator (5% CO2- 9 5%
air, 37℃). The medium was changed following day,
and the cells were further cultured for 5-6 days with
changing medium and culture flask (75 or 150 cm2)
every 2 days. After culture, the cells were detached
and suspended with Trypsin-EDTA solution (0.05%
trypsin, 0.02% EDTA, GIBCO), seeded in 6-well plates
for cell permeation (membrane pore size: 3.0μm ,
T r a n s w e l l®, CORNING) at 2 x 106 cells per well, and
cultured for 3 days. The upper and lower sides of the
cell membrane plate were regarded as the tissue and
vascular sides, respectively. Earle’s M199 Solution
(GIBCO) was used for culture and Earle’s Balanced
Salt Solution (EBSS, GIBCO) for setting of the HSA
concentration and cell membrane permeation
experiment of FP. LLC-PK1 cells were passaged 15-18
times before the experiment. The cell membrane
permeation experiment of FP was triplicate or
quadruplicate (n=3-4). 
2. FP measurement method2 )
FP was measured using high-performance liquid
chromatography (HPLC). All samples excluding free
FP solution were deproteinized with methanol before
injection into HPLC. The HPLC measurement
conditions for FP analysis were as follows: 
HPLC, SHIMADZU CLASS-VP; column, LiChrospher®
RP-18 Select B (5 μm), 250 mm L. x 4.0 mm I.D.;
mobile phase, 0.1 M citric acid - 0.1 M sodium acetate
(pH 4.5): acetonitrile=1:1; flow rate, 1.0 mL/min;
column temperature, 40℃; injection volume, 30 μL ;
excitation, 248 nm; and emission, 320 nm.
3. Setting of HSA concentration 
The culture medium was changed to EBSS on
experiment day (1.5 and 2.6 mL on the upper and
lower sides, respectively). FP (final concentration: l40
μ M) was added to HSA solution at various
concentrations (final concentration: l0, 40, 100, 200,
400, and 600 μM), and the total and free FP levels on
the upper and lower sides were measured every hour
for 4 hours (free FP was measured only at 4 hours).
To measure free FP, the upper and lower solutions
were centrifuged at 3,000 rpm for 10 minutes and
ultrafiltrated (TOSO) to prepare free FP solutions. The
protein binding rate of FP was calculated from the
total and free FP levels. 
4. Cell membrane permeation experiment of FP 
The cultur  medium was changed to EBSS on
experiment day (1.5 and 2.6 mL on the upper and
lo r sides, respectively). 6MNA solution (final
concentration: 50 and 100μM) was added to the HSA
and FP solutions at the final concentrations
establish d on setting the HSA concentration: 200 μM
and 40μM, re p ctively, and the total and free FP
levels in the upper and lower solutions were
mea ured after 2 and 4 hours (free FP was measured
only a  4 hours). In addition, the intracellular FP level
was measured after the experiment. To measure
intrac llular FP, the membrane was detached from the
plat  and washed twice with EBSS in a microtube,
EBSS was removed by sucking, and cells were
dissolved with an equal volume of trypsin (10 x) and
2N NaOH, followed by centrifugation at 3,000 rpm for
10 minutes. The supernatant was then neutralized
with an equal volume of 1N HCl and subjected to FP
meas rement. 
5. Statistical analysis
All values were presented as the means±s ta nd a r d
deviation. For analysis of significance of differences in
the FP levels in the upper and lower solutions,
analys s of covariance was employed, and Fisher’s
PLSD was used for multiple comparison. For analysis
f significance of differences in the free and
intracellular FP levels, non-repeated measures
ANOVA was employed, and Dunnett’s tes  was used
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for multiple comparison. p<0.05 was regarded as
significant. 
RESULTS
1．Setting of HSA concentration 
To evaluate cell membrane permeability of FP in
the presence of 6MNA, the HSA concentration was
established (0, 40, 100, 200, 400, and 600 μM). The
FP levels in the upper solution between 0 and 4
hours are shown in Fig. 1. The HSA addition
markedly reduced the level. The FP levels in the
lower solution at 4 hours are shown in Fig. 2. The
HSA addition markedly increased the level. The
protein binding rates of FP at 4 hours in the lower
solution are shown in Table 1. The protein binding
rate rose as the HSA concentration increased. 
2. Cell membrane permeation experiment of FP
The total FP levels in the upper solution at 0-4
hours are shown in Fig. 3. The total FP level in the
upper solution was significantly increased at 4
hours in the presence of 50μM 6MNA (p<0.05), but
the total level in the presence of 100 μM 6MNA
was lower than that in presence of 50μM 6MNA.
The total FP levels in the lower solution at 0-4
hours are shown in Fig. 4. The total level in the
lower solution was not changed at 2 or 4 hours.
The free FP levels at 4 hours are shown in Fig. 5.
The free FP level in the upper solution was
significantly elevated by the addition of 100μM
6MNA at 4 hours (p<0.01). No significant change
was noted in the free FP level in the lower
solution or in the intracellular level at 4 hours (Fig.
6).
Fig. 1  The FP level (μg/mL) in the upper solution with
changes in the HSA concentration
Fig. 2  The FP level (μg/mL) in the lower solution with
changes in the HSA concentration 
Fig. 3 The FP level (μg/mL) in the upper solution in
the presence of the inhibitor 
The values are presented as the means±
standard error (n=4). 
*; p<0.05
Table 1 The protein binding rate (%) of FP in the lower
solution with changes in the HSA concentration
The values are presented as the means±
standard error. 
DISCUSSION
Cell membrane permeability of FP in the presence
of 6MNA was investigated using swine kidney cell
line LLC-PK1. The addition of 6MNA significantly
elevated the total and free FP levels. 
Since the blood HSA level is about 600μM, the cell
membrane permeability experiment of FP should be
investigated at an HSA concentration of 600μM.
However, HSA is a useful human-derived reagent.
Thus, we investigated the HSA concentration at
which the protein binding rate of FP can be
maintained at 99%, and performed the experiment
at the minimum HSA concentration. A high protein
binding rate of FP was confirmed, as reported by
Tohno et al.1), and the protein binding rate of FP
was 99.9% at HSA concentrations of 200, 400, and
600μM. Based on these, the HSA concentration
was set at 200 μM in this experiment. 
Cell membrane permeability of FP in the
presence of 6MNA was investigated using LLC-
PK1 cells. The 6MNA addition significantly
elevated the total and free FP levels, showing that
cell membrane permeability of FP was increased.
6MNA may have prevented FP from protein
binding by binding to HSA site II, which elevated
the free FP level in the lower solution and
promoted their transfer to the upper solution. 
The total FP level in the upper solution at 4
hours in the presence of 100 μM 6MNA was lower
than that in the presence of 50 μM 6MNA as
shown in Fig. 3. We considered its reason as
follows: The total FP level in the upper solution in
the presence of 100 μM 6MNA tended to be higher
than that in the presence of 50 μM 6MNA at 2
hours as shown in Fig. 3, and the free FP level in
the upper solution was significantly higher than
that in the presence of 50μM 6MNA at 4 hours as
shown in Fig. 5. The total FP level in the upper
solution at 4 hours should have been higher in the
presence of 100 μM 6MNA, but free FP may have
transferred to the lower solution due to its
increased level, reducing the total FP level in the
upper solution. However, no significant changes
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Fig. 5  The free FP levels (μg/mL) in the upper and
lower solutions in the presence of the inhibitor 
The values are presented as the means±standard
error (n=4). **; p<0.01.
Fig. 6  The intracellular FP level (μg) in the presence of
the inhibitor
The values are presented as the means±
standard error (n=4).
Fig. 4 The FP level (μg/mL) in the lower solution in
the presence of the inhibitor 
The values are presented as the means±
standard error (n=4)
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were noted in the total or free FP level in the
lower solution at 4 hours as shown in Figs. 4 and
5, respectively. 
Kawai et al. recently reported that scintigraphy
with a radioactive imaging diagnostic agent, 123I-N-
isopropyl-p-iodoamphetamine (IMP), could be
performed at a low dose using 6MNA in monkeys8).
Both IMP and 6MNA bind to albumin site II. They
utilized the increase in the free IMP level by prior
binding of 6MNA to albumin site II. Their finding
may have been due to increased cell membrane
permeability demonstrated in our study: inhibition
of binding to albumin in blood vessels may have
promoted tissue transfer of IMP. 
6MNA increased cell membrane permeability of
FP by inhibiting protein binding of FP, suggesting
that concomitant nabumetone (prodrug of 6MNA,
Relifen®) enhances transfer of site II-binding drugs,
such as FP, to the target tissue, increasing the
effect at a low dose. The series of our findings
suggest that adequate use of safe protein binding
inhibitors may promote tissue transfer. We are
planning to develop a dose reduction method for
high-risk drugs based on these basic studies and
evidence obtained from various human cells. 
a)This study was partially supported by research
grant from the aluminum association of
Kumamoto University School of Pharmacy. 
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アルブミンサイトⅡ結合阻害薬である6-メトキシ-2-ナフチル酢酸による
フルルビプロフェンの蛋白結合阻害に関する基礎的検討a）
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日本語要旨
非ステロイド性抗炎症薬（N S A I D）フルルビプロフェン（F P）の蛋白結合率は約9 9 %であり、組
織移行性が低い。6 -メトキシ- 2 -ナフチル酢酸（6 M N A ）は、N S A I Dの1つであるナブメトンの活性
代謝産物である。これらの薬物は、ともにヒト血清アルブミン（H S A )のサイトⅡに強く結合する。
私たちは、L L C - P K 1を用いて6 M N A 添加時のF Pの細胞膜透過性について調べた。この実験では、細
胞膜プレートの上側を組織側、下側を血管側と想定した。下側のF Pを含むH S A 溶液に6 M N A を添加
後、上側、下側のF P濃度を測定した。上側へのF Pの移行量は6 M N A の添加により、Total FPおよび
Free FP濃度ともに有意な増加を示した。下側の量は変化が見られなかった。臨床におけるナブメト
ンの併用はF PのようなサイトⅡ結合性薬物の標的組織への移行量を増加させ、少量においても効果
を高める可能性が示唆された。
キーワード：ヒト血清アルブミン, 蛋白結合, サイトⅡ, フルルビプロフェン, 6-メトキシ-2-ナフチル酢酸
